Vol. 4 No. 12 (2024)
Reimbursement Recommendations

Enfortumab Vedotin (Padcev)

decorative image of the issue cover

Published December 17, 2024

Key Messages

  • The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) recommends that public drug programs reimburse Padcev, in combination with pembrolizumab, for treating patients with locally advanced urothelial cancer (UC) or metastatic urothelial cancer (mUC).
  • Padcev, in combination with pembrolizumab, should only be covered to treat adult patients with unresectable locally advanced UC or mUC with no prior systemic therapy for mUC and who are in relatively good health. Eligible patients include those who have received chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant) and experienced disease recurrence more than 12 months after the completion of treatment or received adjuvant immunotherapy with nivolumab and experienced disease recurrence more than 6 months after the completion of treatment.
  • Padcev, in combination with pembrolizumab, should only be reimbursed if prescribed by a clinician who has experience treating patients with locally advanced UC or mUC and if the price of Padcev is reduced.